Loading...
| A15003 | Pages: 173 | Dec 2021 | 207 Views | | |
| Author(s) : Sushant Terdale, Avinash Gadekar , Onkar Sumant | Tables: 45 | Charts: 69 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the France Cardiovascular Ultrasound Market
Request Now !The France cardiovascular ultrasound market was valued at $162.97 million in 2020, and is projected to reach $252.90 million by 2030, registering a CAGR of 4.7% from 2021 to 2030. The growth of the France cardiovascular ultrasound market is driven by increase in incidence of cardiovascular diseases, change in the lifestyle of the population, rise in the number of hospitals and clinics. Moreover, surge in the geriatric population and rise in number of product launches associated to the cardiovascular ultrasound also contributes to the growth of the market.
In addition, rise in health awareness toward cardiovascular diseases among the adult population supplements the market growth. However, factors such as economic influence of approving new technologies and insufficient reimbursement scenario impede the growth of the France cardiovascular ultrasound market. Conversely, technological advancements leading in cardiac specific technologies such as tissue enhancements, lateral gain control, advanced dynamic flow, tissue Doppler, and stress echo provide lucrative opportunities for the growth of the market.
Get more information on this report : Request Sample Pages
A cardiovascular ultrasound is an ultrasound that looks specifically at your heart and blood vessels. This type of imaging can be used to assess the function of different parts of your cardiovascular system. The cardiovascular ultrasound is a useful tool to evaluate the structure and function of the heart and associated vessels. It is a fast, easy, and painless evaluation that uses ultrasound waves to produce images of the heart. Cardiac ultrasound device is relatively inexpensive, lightweight, and portable device and offers the features that overcome the need of physical examination.
Coronavirus (COVID-19) was discovered in late December in Hubei province of Wuhan city in China. The disease is caused by a virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted from humans to humans. The ultrasound device manufacturing was disturbed in 2020 due to the slowdown of distribution chain of raw materials. Moreover, the manpower needed for the manufacturing plants could not come to work due to lockdown imposed, which shut down the manufacturing plants of the ultrasound devices.
Overall impact of the COVID-19 pandemic on the France cardiovascular ultrasound market was recorded to be negative owing to the factors such as disturbance in the distribution chain, financial problems, scarcity of laborers at manufacturing plants, and decrease in the number of ultrasound diagnosis performed amid the pandemic. However, this situation is expected to change post COVID-19 pandemic in the coming years.
The France cardiovascular ultrasound market is segmented into clinical application, technology, device display, age group, and end user. On the basis of clinical application, the market is categorized into diagnostic cardiology, interventional cardiology, and vascular diagnostic. Diagnostic cardiology is further categorized as transthoracic echocardiogram, transesophageal echocardiogram, stress echocardiogram, and other echocardiogram. Interventional cardiology is further categorized as electrophysiology procedure, septal closure procedure, and others.
Vascular diagnostic is further categorized as aortoiliac duplex, carotid duplex, lower extremity arterial duplex, iliocaval duplex, and mesenteric duplex. By technology, it is classified into 2D, 3D & 4D, and doppler imaging. By device display, it is classified into color display and black & white display. By age group, it is classified into adult and pediatric. By end user, it is classified into private clinics, public hospitals, cardiology centers, and ambulatory centers.
By clinical application, the diagnostic cardiology segment dominated the France cardiovascular ultrasound market in 2020, and is anticipated to continue this trend during the forecast period. Key factors such as increase in the prevalence of heart diseases, development of new & advanced cardiovascular ultrasound devices, and rise in focus toward diagnosis through ultrasound devices is expected to drive the growth of the segment.
By technology, it is classified into 2D, 3D & 4D, and doppler imaging. The 2D segment accounted for maximum France cardiovascular ultrasound market revenue in 2020, and is anticipated to maintain its dominance during the forecast period. This is attributed to increase in the geriatric population and change in lifestyle of the people. However, the 3D & 4D segment exhibits fastest growth from 2021 to 2030 owing to increase in the number of heart patients and rise in the awareness of diagnosis via ultrasound devices. Moreover, availability of large number of advanced hospitals, presence of skilled medical professionals, large number of ambulatory centers, and wide usage of medical nonwoven products are anticipated to drive the growth of the segment.
By device display, it is classified into color display and black and white display. The color display segment accounted for maximum market revenue in 2020, and is anticipated to maintain its dominance during the forecast period. This is attributed to the increased use of color display and rise in the benefits of color display which is expected to drive the France cardiovascular ultrasound market growth.
Get more information on this report : Request Sample Pages
By age group, it is classified into adult and pediatric. The adult segment accounted for maximum market revenue in 2020, and is anticipated to maintain its dominance during the forecast period. This is attributed to the increased population of adult people and surge in incidence of cardiovascular diseases (CVDs) in that age group, which is expected to drive the market growth.
By end user, it is classified into private clinics, public hospitals, cardiology centers, and ambulatory centers. The public hospitals segment accounted for maximum market revenue in 2020, and is anticipated to maintain its dominance during the forecast period. This is attributed to the increase in the number of hospitals and clinics and increase in number of government initiatives for the treatment. However, the cardiology centers segment exhibits fastest growth from 2021 to 2030 owing to increase in the number of healthcare centers and surge in incidences of heart diseases. Moreover, availability of number of advanced hospitals, presence of skilled professionals, and wide usage of ultrasound are anticipated to drive the growth of the France cardiovascular ultrasound market segment.
Get more information on this report : Request Sample Pages
Key Benefits for Stakeholders
Key Market Segments
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five force analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Increase in incidence of cardiovascular diseases (CVDs)
3.4.1.2.Advantages of echocardiography over invasive cardiac diagnostic procedures
3.4.1.3.Increase in geriatric population
3.4.2.Restraint
3.4.2.1.Stringent government regulations
3.4.3.Opportunities
3.4.3.1.Technological advancements in cardiovascular ultrasound systems
3.4.4.Impact analysis
3.5.COVID-19 Impact Analysis on France cardiovascular ultrasound Market
CHAPTER 4:FRANCE CARDIOVASCULAR ULTRASOUND MARKET, BY CLINICAL APPLICATION
4.1.Overview
4.1.1.Market size and forecast
4.2.Diagnostic Cardiology
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast
4.2.3.Market size and forecast, by test type
4.2.3.1.Transthoracic Echocardiogram
4.2.3.1.1.Market size and forecast
4.2.3.2.Transesophageal Echocardiogram
4.2.3.2.1.Market size and forecast
4.2.3.3.Stress Echocardiogram
4.2.3.3.1.Market size and forecast
4.2.3.4.Other Echocardiogram
4.2.3.4.1.Market size and forecast
4.3.Interventional Cardiology
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market size and forecast, by test type
4.3.3.1.Electrophysiology procedure
4.3.3.1.1.Market size and forecast
4.3.3.2.Septal closure procedure
4.3.3.2.1.Market size and forecast
4.3.3.3.Others
4.3.3.3.1.Market size and forecast
4.4.Vascular Diagnostic
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market size and forecast, by test type
4.4.3.1.Aortoiliac Duplex
4.4.3.1.1.Market size and forecast
4.4.3.2.Carotid Duplex
4.4.3.2.1.Market size and forecast
4.4.3.3.Lower Extremity Arterial Duplex
4.4.3.3.1.Market size and forecast
4.4.3.4.Iliocaval Duplex
4.4.3.4.1.Market size and forecast
4.4.3.5.Mesenteric Duplex
4.4.3.5.1.Market size and forecast
CHAPTER 5:FRANCE CARDIOVASCULAR ULTRASOUND MARKET, BY TECHNOLOGY
5.1.Overview
5.1.1.Market size and forecast
5.2.2D
5.2.1.Market size and forecast
5.3.3D& 4D
5.3.1.Market size and forecast
5.4.Doppler Imaging
5.4.1.Market size and forecast
CHAPTER 6:FRANCE CARDIOVASCULAR ULTRASOUND MARKET, BY DEVICE DISPLAY
6.1.Overview
6.1.1.Market size and forecast
6.2.Color Display
6.2.1.Market size and forecast
6.3.Black &White Display
6.3.1.Market size and forecast
CHAPTER 7:FRANCE CARDIOVASCULAR ULTRASOUND MARKET, BY AGE GROUP
7.1.Overview
7.1.1.Market size and forecast
7.2.Adult
7.2.1.Market size and forecast
7.3.Pediatric
7.3.1.Market size and forecast
CHAPTER 8:FRANCE CARDIOVASCULAR ULTRASOUND MARKET, BY END USER
8.1.Overview
8.1.1.Market size and forecast
8.2.Private Clinics
8.2.1.Market size and forecast
8.2.2.Market size and forecast, by clinical application
8.2.2.1.Diagnostic cardiology
8.2.2.1.1.Market size and forecast
8.2.2.2.Interventional cardiology
8.2.2.2.1.Market size and forecast
8.2.2.3.Vascular diagnostic
8.2.2.3.1.Market size and forecast
8.3.Public Hospitals
8.3.1.Market size and forecast
8.3.2.Market size and forecast, by clinical application
8.3.2.1.Diagnostic cardiology
8.3.2.1.1.Market size and forecast
8.3.2.2.Interventional cardiology
8.3.2.2.1.Market size and forecast
8.3.2.3.Vascular diagnostic
8.3.2.3.1.Market size and forecast
8.4.Cardiology centers
8.4.1.Market size and forecast
8.4.2.Market size and forecast, by clinical application
8.4.2.1.Diagnostic cardiology
8.4.2.1.1.Market size and forecast
8.4.2.2.Interventional cardiology
8.4.2.2.1.Market size and forecast
8.4.2.3.Vascular diagnostic
8.4.2.3.1.Market size and forecast
8.5.Ambulatory centers
8.5.1.Market size and forecast
8.5.2.Market size and forecast, by clinical application
8.5.2.1.Diagnostic cardiology
8.5.2.1.1.Market size and forecast
8.5.2.2.Interventional cardiology
8.5.2.2.1.Market size and forecast
8.5.2.3.Vascular diagnostic
8.5.2.3.1.Market size and forecast
CHAPTER 9:COMPANY PROFILES
9.1.CANON INC. (CANON MEDICAL SYSTEM CORPORATION)
9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product portfolio
9.1.5.Business performance
9.1.6.Key strategic moves and developments
9.2.ESAOTE S.P.A
9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Operating business segments
9.2.4.Product portfolio
9.2.5.Key strategic moves and developments
9.3.FUJIFILM HOLDING CORPORATION
9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business segments
9.3.4.Product portfolio
9.3.5.Business performance
9.4.GENERAL ELECTRIC COMPANY
9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Operating business segments
9.4.4.Product portfolio
9.4.5.Business performance
9.5.HITACHI LTD.
9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Operating business segments
9.5.4.Product portfolio
9.5.5.Business performance
9.6.KONINKLIJKE PHILIPS N.V.
9.6.1.Company overview
9.6.2.Company snapshot
9.6.3.Operating business segments
9.6.4.Product portfolio
9.6.5.Business performance
9.6.6.Key strategic moves and developments
9.7.MINDRAY MEDICAL INTERNATIONAL LIMITED
9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segments
9.7.4.Product portfolio
9.8.SAMSUNG GROUP
9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio
9.8.5.Business performance
9.9.SIEMENS AG
9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product portfolio
9.9.5.Business performance
9.10.SUPERSONIC IMAGINE
9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product portfolio
9.10.5.Business performance
LIST OF TABLES
TABLE 01.FRANCE CARDIOVASCULAR ULTRASOUND MARKET, BY CLINICAL APPLICATION, 2020-2030 ($MILLION)
TABLE 02.FRANCE CARDIOVASCULAR ULTRASOUND MARKET FOR DIAGNOSTIC CARDIOLOGY, BY TEST TYPE 2020–2030 ($MILLION)
TABLE 03.FRANCE CARDIOVASCULAR ULTRASOUND MARKET FOR INTERVENTIONAL CARDIOLOGY, BY TEST TYPE 2020–2030 ($MILLION)
TABLE 04.FRANCE CARDIOVASCULAR ULTRASOUND MARKET FOR VASCULAR DIAGNOSTIC, BY TEST TYPE 2020–2030 ($MILLION)
TABLE 05.FRANCE CARDIOVASCULAR ULTRASOUND MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 06.FRANCE CARDIOVASCULAR ULTRASOUND MARKET, BY DEVICE DISPLAY, 2020–2030 ($MILLION)
TABLE 07.FRANCE CARDIOVASCULAR ULTRASOUND MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 08.FRANCE CARDIOVASCULAR ULTRASOUND MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 09.FRANCE CARDIOVASCULAR ULTRASOUND MARKET FOR PRIVATE CLINICS, BY CLINICAL APPLICATION 2020–2030 ($MILLION)
TABLE 10.FRANCE CARDIOVASCULAR ULTRASOUND MARKET FOR PUBLIC HOSPITALS, BY CLINICAL APPLICATION 2020–2030 ($MILLION)
TABLE 11.FRANCE CARDIOVASCULAR ULTRASOUND MARKET FOR CARDIOLOGY CENTERS, BY CLINICAL APPLICATION 2020–2030 ($MILLION)
TABLE 12.FRANCE CARDIOVASCULAR ULTRASOUND MARKET FOR AMBULATORY CENTERS, BY CLINICAL APPLICATION 2020–2030 ($MILLION)
TABLE 13.CANON: COMPANY SNAPSHOT
TABLE 14.CANON: OPERATING SEGMENTS
TABLE 15.CANON: PRODUCT PORTFOLIO
TABLE 16.CANON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 17.ESAOTE: COMPANY SNAPSHOT
TABLE 18.ESAOTE: OPERATING SEGMENTS
TABLE 19.ESAOTE: PRODUCT PORTFOLIO
TABLE 20.ESAOTE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 21.FUJIFILM: COMPANY SNAPSHOT
TABLE 22.FUJIFILM: OPERATING SEGMENTS
TABLE 23.FUJIFILM: PRODUCT PORTFOLIO
TABLE 24.GENERAL ELECTRIC: COMPANY SNAPSHOT
TABLE 25.GENERAL ELECTRIC: OPERATING SEGMENTS
TABLE 26.GENERAL ELECTRIC: PRODUCT PORTFOLIO
TABLE 27.HITACHI: COMPANY SNAPSHOT
TABLE 28.HITACHI: OERATING SEGMENT
TABLE 29.HITACHI.: PRODUCT PORTFOLIO
TABLE 30.PHILLIPS: COMPANY SNAPSHOT
TABLE 31.PHILLIPS: OPERATING SEGMENTS
TABLE 32.PHILLIPS: PRODUCT PORTFOLIO
TABLE 33.PHILLIPS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 34.MINDRAY: COMPANY SNAPSHOT
TABLE 35.MINDRAY: OPERATING SEGMENTS
TABLE 36.MINDRAY: PRODUCT PORTFOLIO
TABLE 37.SAMSUNG: COMPANY SNAPSHOT
TABLE 38.SAMSUNG: OPERATING SEGMENTS
TABLE 39.SAMSUNG: PRODUCT PORTFOLIO
TABLE 40.SIEMENS: COMPANY SNAPSHOT
TABLE 41.SIEMENS: OPERATING SEGMENTS
TABLE 42.SIEMENS: PRODUCT PORTFOLIO
TABLE 43.SUPERSONIC: COMPANY SNAPSHOT
TABLE 44.SUPERSONIC: OPERATING SEGMENTS
TABLE 45.SUPERSONIC: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.FRANCE CARDIOVASCULAR ULTRASOUND MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.HIGH INTENSITY OF RIVALRY
FIGURE 11.IMPACT ANALYSIS
FIGURE 12.FRANCE CARDIOVASCULAR ULTRASOUND MARKET FOR DIAGNOSTIC CARDIOLOGY, 2020–2030 ($MILLION)
FIGURE 13.FRANCE TRANSTHORACIC ECHOCARDIOGRAM MARKET, 2020–2030 ($MILLION)
FIGURE 14.FRANCE TRANSESOPHAGEAL ECHOCARDIOGRAM MARKET, 2020–2030 ($MILLION)
FIGURE 15.FRANCE STRESS ECHOCARDIOGRAM MARKET, 2020–2030 ($MILLION)
FIGURE 16.FRANCE OTHER ECHOCARDIOGRAM MARKET, 2020–2030 ($MILLION)
FIGURE 17.FRANCE CARDIOVASCULAR ULTRASOUND MARKET FOR INTERVENTIONAL CARDIOLOGY, 2020–2030 ($MILLION)
FIGURE 18.FRANCE ELECTROPHYSIOLOGY PROCEDURES MARKET, 2020–2030 ($MILLION)
FIGURE 19.FRANCE SEPTAL CLOSURE PROCEDURE MARKET, 2020–2030 ($MILLION)
FIGURE 20.FRANCE OTHERS SMARKET, 2020–2030 ($MILLION)
FIGURE 21.FRANCE CARDIOVASCULAR ULTRASOUND MARKET FOR VASCULAR DIAGNOSTIC, 2020–2030 ($MILLION)
FIGURE 22.FRANCE AORTOILIAC DUPLEX MARKET, 2020–2030 ($MILLION)
FIGURE 23.FRANCE CAROTID DUPLEX MARKET, 2020–2030 ($MILLION)
FIGURE 24.FRANCE LOWER EXTREMITY ARTERIAL DUPLEX MARKET, 2020–2030 ($MILLION)
FIGURE 25.FRANCE ILIOCAVAL DUPLEX MARKET, 2020–2030 ($MILLION)
FIGURE 26.FRANCE MESENTERIC DUPLEX MARKET, 2020–2030 ($MILLION)
FIGURE 27.FRANCE 2D CARDIOVASCULAR ULTRASOUND MARKET, 2020–2030 ($MILLION)
FIGURE 28.FRANCE 3D & 4D CARDIOVASCULAR ULTRASOUND MARKET, 2020–2030 ($MILLION)
FIGURE 29.FRANCE DOPPLER IMAGING CARDIOVASCULAR ULTRASOUND MARKET, 2020–2030 ($MILLION)
FIGURE 30.FRANCE COLOR DISPLAY CARDIOVASCULAR ULTRASOUND MARKET, 2020–2030 ($MILLION)
FIGURE 31.FRANCE BLACK & WHITE DISPLAYCARDIOVASCULAR ULTRASOUND MARKET, 2020–2030 ($MILLION)
FIGURE 32.FRANCE CARDIOVASCULAR ULTRASOUND MARKET FOR ADULT, 2020–2030 ($MILLION)
FIGURE 33.FRANCE CARDIOVASCULAR ULTRASOUND MARKET, FOR PEDIATRIC, 2020–2030 ($MILLION)
FIGURE 34.FRANCE CARDIOVASCULAR ULTRASOUND MARKET FOR PRIVATE CLINICS, 2020–2030 ($MILLION)
FIGURE 35.FRANCE DIAGNOSTIC CARDIOLOGY CARDIOVASCULAR ULTRASOUND MARKET FOR PRIVATE CLINICS, 2020–2030 ($MILLION)
FIGURE 36.FRANCE INTERVENTIONAL CARDIOLOGY CARDIOVASCULAR ULTRASOUND MARKET FOR PRIVATE CLINICS, 2020–2030 ($MILLION)
FIGURE 37.FRANCE VASCULAR DIAGNOSTIC CARDIOVASCULAR ULTRASOUND MARKETFOR PRIVATE CLINICS, 2020–2030 ($MILLION)
FIGURE 38.FRANCE CARDIOVASCULAR ULTRASOUND MARKET FOR PUBLIC HOSPITALS, 2020–2030 ($MILLION)
FIGURE 39.FRANCE DIAGNOSTIC CARDIOLOGY CARDIOVASCULAR ULTRASOUND MARKET FOR PUBLIC HOSPITALS, 2020–2030 ($MILLION)
FIGURE 40.FRANCE INTERVENTIONAL CARDIOLOGY CARDIOVASCULAR ULTRASOUND MARKET FOR PUBLIC HOSPITALS, 2020–2030 ($MILLION)
FIGURE 41.FRANCE VASCULAR DIAGNOSTIC CARDIOVASCULAR ULTRASOUND MARKET FOR PUBLIC HOSPITALS, 2020–2030 ($MILLION)
FIGURE 42.FRANCE CARDIOVASCULAR ULTRASOUND MARKET FOR CARDIOLOGY CENTERS , 2020–2030 ($MILLION)
FIGURE 43.FRANCE DIAGNOSTIC CARDIOLOGY CARDIOVASCULAR ULTRASOUND MARKET FOR CARDIOLOGY CENTERS, 2020–2030 ($MILLION)
FIGURE 44.FRANCE INTERVENTIONAL CARDIOLOGY CARDIOVASCULAR ULTRASOUND MARKET FOR CARDIOLOGY CENTERS, 2020–2030 ($MILLION)
FIGURE 45.FRANCE VASCULAR DIAGNOSTIC CARDIOVASCULAR ULTRASOUND MARKET FOR CARDIOLOGY CENTERS, 2020–2030 ($MILLION)
FIGURE 46.FRANCE CARDIOVASCULAR ULTRASOUND MARKET FOR AMBULATORY CENTERS, 2020–2030 ($MILLION)
FIGURE 47.FRANCE DIAGNOSTIC CARDIOLOGY CARDIOVASCULAR ULTRASOUND MARKET FOR AMBULATORY CENTERS, 2020–2030 ($MILLION)
FIGURE 48.FRANCE INTERVENTIONAL CARDIOLOGY CARDIOVASCULAR ULTRASOUND MARKET FOR AMBULATORY CENTERS, 2020–2030 ($MILLION)
FIGURE 49.FRANCE VASCULAR DIAGNOSTIC CARDIOVASCULAR ULTRASOUND MARKET FOR AMBULATORY CENTERS, 2020–2030 ($MILLION)
FIGURE 50.CANON: NET SALES, 2018–2020 ($MILLION)
FIGURE 51.CANON: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 52.CANON: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 53.FUJIFILM: NET SALES, 2018–2020 ($MILLION)
FIGURE 54.FUJIFILM: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 55.GENERAL ELECTRIC: NET SALES, 2018–2020 ($MILLION)
FIGURE 56.GENERAL ELECTRIC: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 57.GENERAL ELECTRIC: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 58.HITACHI: NET SALES, 2018–2020 ($MILLION)
FIGURE 59.HITACHI: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 60.HITACHI: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 61.PHILLIPS: NET SALES, 2018–2020 ($MILLION)
FIGURE 62.PHILLIPS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 63.PHILLIPS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 64.SAMSUNG: NET SALES, 2018–2020 ($MILLION)
FIGURE 65.SIEMENS: NET SALES, 2019–2021 ($MILLION)
FIGURE 66.SIEMENS: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 67.SIEMENS: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 68.SUPERSONIC: NET SALES, 2018–2020 ($MILLION)
FIGURE 69.SUPERSONIC: REVENUE SHARE BY SEGMENT, 2021 (%)
The cardiovascular ultrasound is painless and non-invasive test that uses sound waves to create 2D and 3D images of the cardiovascular system. It produces information about the velocity of blood flow in the heart and measures heart valve function. A transducer is placed on the chest wall of the patient in order to transmit and receive acoustic signals. The size of all four heart chambers is measured and left &right heart chamber function is assessed. Echocardiography is simple, quick, and radiation &risk-free. Machines are mobile and can hence be used everywhere. The major factors that drive the growth of the France cardiovascular ultrasound market are surge in incidences of cardiovascular diseases, increased adult population, rise in public awareness to prevent heart problems, and surge in number of products launched. In addition, growth in demand for ultrasound, presence of major players of ultrasound in France, and favorable government initiatives regarding health care are expected to drive the growth of the France cardiovascular ultrasound market.
A. The total market value of France cardiovascular ultrasound market is $252.90 million in 2030.
A. No, there is no value chain analysis provided in the France Cardiovascular Ultrasound Market Report
A. Diagnostic cardiology segment is the most influencing segment owing to the increasing prevalence of cardiovascular diseases, increasing the incidences of heart diseases, increasing demand of ultrasound procedures.
A. The forcast period for France cardiovascular ultrasound market is 2020 to 2030
A. The market value of France cardiovascular ultrasound market in 2020 is $162.97 million.
A. The base year is 2020 in France cardiovascular ultrasound market
A. Increasing prevalence of cardiovascular diseases, increasing new and advanced product launches are the key trends in the France cardiovascular ultrasound market report.
A. Increasing prevalence of cardiovascular diseases, increasing new and advanced product launches are the key trends in the France cardiovascular ultrasound market report.
A. France has the highest growth rate of 4.7% in the market which is growing due to increase in the prevalence of cardiovascular diseases in France, presence of market players in France.
A. Yes, the France cardiovascular ultrasound market companies are profiled in the report.
A. Yes, the France cardiovascular ultrasound market report provides PORTER Analysis
Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
